About Avillion
Avillion is a company based in London (United Kingdom) founded in 2012. The company has 2 employees. Avillion offers products and services including Clinical Trial Management, Regulatory Expertise, and Quality Assurance. Avillion operates in a competitive market with competitors including Emmes, Syneos Health, Veristat, ClinChoice and Medelis WCCT Global, among others.
- Headquarter London, United Kingdom
- Employees 2
- SectorsHealthcare
- Email••••••••
- Website avillionllp.com
- Social LinkedIn
- Legal Name Avillion Llp
- Date of Incorporation 05 Oct, 2012
- Jurisdiction LONDON, ENGLAND
- InvestorsBlackstone
& 2 more
- Employee Count2
Products & Services of Avillion
Avillion offers a comprehensive portfolio of products and services, including Clinical Trial Management, Regulatory Expertise, and Quality Assurance.
End-to-end management of global clinical trials for drug development.
Strategic guidance for regulatory submissions across various markets.
Ensuring high standards in drug development processes and monitoring.
Funding Insights of Avillion
- Total Rounds 2
- Investors Count 3
All 2 funding rounds of Avillion with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2014 | – | Series A | – | – | |
| Jan 2013 | – | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Avillion
Avillion has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Blackstone, Royalty Pharma and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in marketed and late-stage biopharmaceutical companies. | 1996 | royaltypharma.com | New York, United States | |
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States |
Investor details for Avillion
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Avillion
1 people are tracked at Avillion (1 in leadership); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
Allison Jeynes-Ellis | CEO | Leadership |
Complete people profiles for Avillion
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Avillion
3 dated milestones of Avillion across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Avillion is founded.
- Funding First funding round.
- Funding Latest funding round, Series A,.
Competitors of Avillion
Avillion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Emmes, Syneos Health, Veristat, ClinChoice and Medelis WCCT Global, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| emmes.com | 1977 | United States | – | 195 | Outsourced contract research organization services are provided to clients. | |
| syneoshealth.com | 1984 | Raleigh, United States | – | 29,395 | CRO clinical development services are provided by Syneos Health. | |
| veristat.com | 1994 | Southborough, United States | – | 7 | Clinical trials and regulatory submissions are supported as a CRO. | |
| clinchoice.com | 1995 | Fort Washington, United States | $212M | 478 | CRO focused on data management, regulatory affairs and consulting services | |
| wcct.com | 1998 | Cypress, United States | $17M | 229 | Full-service CRO expertise in influenza and oncology research is offered. | |
| parexel.com | 1983 | Waltham, United States | – | – | Full-service clinical research organization services are provided globally by Parexel. | |
| celgene.com | 1986 | Summit, United States | $45M | 4,891 | Therapies for cancer and inflammatory diseases are developed. | |
| hvivo.com | 1998 | London, United Kingdom | – | 133 | Provider of cell based assays, field trial, and molecular services for biopharma sector |
Detailed competitors of Avillion
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Avillion
Websites that share an audience with Avillion (avillionllp.com).
Websites whose visitors overlap most with Avillion. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Latest news on Avillion
Complete news archive for Avillion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Avillion
10 companies that operate in the same segment as Avillion (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Avillion
Avillion was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Avillion is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Allison Jeynes-Ellis is the current CEO of Avillion.
Avillion has 2 employees.
Avillion, provides clinical co-development services.The company partners with pharmaceutical and biotechnology companies to co-develop and finance late-stage therapeutics. The companys services enable its partners to develop drugs without increasing the burden on their (partners) PL or cash reserves. As per the licencing agreement, the partners maintain absolute ownership of and control on commercialising the asset, while Avillion incurs 100 of the clinical and regulatory risk during the development of late-stage assets. The company receives milestone payments post-commercialisation of the successfully developed products. Avillion is backed by Abingworth, Clarus Ventures and Royalty Pharma. In December 2016, Avillion and Pfizer announced positive results from the Phase 3 BFORE trial demonstrating the superiority of BOSULIF (bosutinib) over Imatinib as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph) chronic myeloid leukaemia (CML).
Avillion's top competitors include Emmes, Syneos Health and ClinChoice.
Avillion offers Clinical Trial Management, Regulatory Expertise, and Quality Assurance.
Avillion has 3 investors. Key investors include Blackstone, Royalty Pharma, and Abingworth.
Avillion operates through Avillion Llp.